Logo

Myriad Genetics: Paul Diaz

Aug 13, 2020

Myriad Genetics has appointed Paul Diaz as its new president and CEO, effective Aug. 13, 2020. Diaz, who will also serve on Myriad's board of directors, will take over from Bryan Riggsbee, who has been serving as the company's interim president and CEO, and CFO after Mark Capone's resignation from that post in February. Diaz served as president, CEO, and in various other roles at Kindred Healthcare, a provider of post-acute healthcare services, for more than a decade. He was also a partner at the private equity firm Cressey & Company LP, and has served as an executive and board member at multiple public and private companies. He is currently on the board of DaVita and a member of the board of trustees of Johns Hopkins Medicine. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.